Eterna Therapeutics To Present at The ASGCT 27th Annual Meeting On Development Of Beta 2 Microglobulin-Knockout IMSC Line With Enhanced Immunosuppressive Activity And Stealthing Features
Eterna Therapeutics To Present at The ASGCT 27th Annual Meeting On Development Of Beta 2 Microglobulin-Knockout IMSC Line With Enhanced Immunosuppressive Activity And Stealthing Features
Eterna Therapeutics To Present at The ASGCT 27th Annual Meeting On Development Of Beta 2 Microglobulin-Knockout IMSC Line With Enhanced Immunosuppressive Activity And Stealthing Features That May Further Augment The Therapeutic Potential Of MSCs In Inflammatory Diseases
Eterna Therapeutics将在ASGCT第27届年会上介绍β2微球蛋白基因敲除IMSC系列的开发情况，该系列具有增强的免疫抑制活性和隐身功能，可能会进一步增强间充质干细胞在炎性疾病中的治疗潜力
- The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cells
- The presentation is on Saturday, May 11th, 2024
- 该演讲报告了具有增强免疫抑制活性和隐身特征的β2微球蛋白基因敲除（B2M-KO）iMSC系列的开发情况，该系列可以通过排除批次间的不一致性、促进体内持久性和增强细胞的效应器功能，进一步增强间充质干细胞治疗炎症性疾病的治疗潜力
- 演讲将于 2024 年 5 月 11 日星期六举行
CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announces that Raven Hinkel will present at the 27th Annual Meeting of the American Society of Gene & Cell Therapy, taking place in Baltimore, Maryland.
马萨诸塞州剑桥，2024年5月7日（环球新闻专线）——使用先进细胞工程技术开发变革性新药的生物制药公司Eterna Therapeutics Inc.（纳斯达克股票代码：ERNA）（“Eterna” 或 “公司”）今天宣布，雷文·欣克尔将出席在马里兰州巴尔的摩举行的美国基因与细胞疗法学会第27届年会。
While mesenchymal stem cells (MSCs) have repeatedly demonstrated significant therapeutic potential in numerous preclinical models, their clinical translation has been greatly impeded by variability in therapeutic responses. This variability is often attributed to donor and source heterogeneity and limited expansion potential. Furthermore, MSCs can exhibit limited in vivo persistence due to clearance by host immune cells, which can also contribute to deficient therapeutic responses. Induced pluripotent stem cell (iPSC)-derived MSCs (iMSCs) promise to directly address many of the fundamental challenges facing MSC translation.
尽管间充质干细胞（MSC）在许多临床前模型中一再显示出巨大的治疗潜力，但其临床转化却因治疗反应的变异而受到极大阻碍。这种变异性通常归因于捐赠者和来源的异质性以及有限的扩张潜力。此外，由于宿主免疫细胞的清除，间充质干细胞在体内的持久性可能有限，这也可能导致治疗反应不足。诱导多能干细胞 (iPSC) 衍生的间充质干细胞 (IMSC) 有望直接解决 MSC 翻译面临的许多基本挑战。
Here, we report the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cells.
在这里，我们报告了一种具有增强免疫抑制活性和隐身特征的β2微球蛋白基因敲除（B2M-KO）iMSC系列的开发情况，该系列可以通过排除批次间的不一致性、促进体内持久性和增强细胞的效应功能，进一步增强间充质干细胞治疗炎症性疾病的治疗潜力。
The abstract concludes that B2M-KO iMSCs are more likely to evade immune clearance and exert their immunomodulatory effects, as demonstrated by their enhanced sensitivity of IDO1 expression and their improved ability to inhibit PBMC proliferation. Our data suggest that B2M-KO iMSCs may be a promising therapeutic agent for T-cell mediated autoimmune and inflammatory indications.
摘要得出结论，B2M-KO IMSC更有可能逃避免疫清除并发挥其免疫调节作用，其增强的IDO1表达灵敏度以及抑制PBMC增殖的能力提高就证明了这一点。我们的数据表明，B2M-KO IMSC可能是治疗T细胞介导的自身免疫和炎症适应症的有前途的治疗药物。
"We are thrilled to advance our iMSC research," says Sanjeev Luther, President and CEO. "iPSC-Derived iMSCs drive our Multiple Sclerosis pipeline candidate and are an important scientific focus for our team."
总裁兼首席执行官桑杰夫·路德说：“我们很高兴能推进我们的iMSC研究。”“iPSC衍生的IMSC推动了我们的多发性硬化症候选药物的发展，也是我们团队重要的科学重点。”
Presentation Details
演示详情
Title: iMSCs Derived from mRNA-Engineered B2M-KO iPSCs Exhibit Enhanced Immunosuppressive Activity and Stealthing Features
标题：源自 mRNA 设计的 B2M-KO iPSC 的 IMSC 具有增强的免疫抑制活性和隐身特性
Presenter: Raven Dance Hinkel, Research Associate II
主持人：Raven Dance Hinkel，二级研究助理
Date: Saturday, May 11, 2024
日期：2024 年 5 月 11 日星期六
Time: 10:30am - 10:45am
时间：上午 10:30-上午 10:45
Session Title: Novel Immune Effector Cell Manufacturing
会议标题：新型免疫效应细胞制造
Session Room: Ballroom 2
会议室：宴会厅 2
Location: Baltimore Convention Center in Baltimore, MD
地点：马里兰州巴尔的摩的巴尔的摩会议中心
译文内容由第三方软件翻译。